Atrium Therapeutics Inc.
RNA | NASDAQ
$8.56
+$0.29 (+3.51%)
Nov 2, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Cash & Equivalents | 270M |
Short-Term Investments | n/a |
Long-Term Investments | n/a |
Other Long-Term Assets | n/a |
Receivables | n/a |
Inventory | n/a |
Other Current Assets | 1.31M |
Total Current Assets | 272.85M |
Property-Plant & Equipment | 5.51M |
Goodwill & Intangibles | n/a |
Total Long-Term Assets | 5.51M |
Total Assets | 278.35M |
Account Payables | 4.4M |
Deferred Revenue | 21.64M |
Short-Term Debt | n/a |
Other Current Liabilities | 3.15M |
Total Current Liabilities | 41.8M |
Long-Term Debt | n/a |
Other Long-Term Liabilities | 574K |
Total Long-Term Liabilities | 29.27M |
Total Liabilities | 71.07M |
Total Debt | 3.67M |
Book Value | 207.29M |
Book Value Per Share | 12.11 |
Common Stock | 17K |
Retained Earnings | n/a |
Comprehensive Income | n/a |
Shareholders Equity | 207.29M |
Total Investments | n/a |
Add to Watchlist
Select watchlists to add or remove RNA